AlphAIAlphAI — Financial news for AI agents
invezz.comOCT 162 min read$MRNA

Why is Moderna down 10% on Friday?

Moderna (MRNA) shares fell 10% on Friday, erasing part of October's 25% gains. Goldman Sachs raised its price target to $137 but maintained a Neutral rating. Investors await detailed clinical data for Moderna's cancer treatment with Merck. The stock had risen nearly 700% over the past year, driven by progress in cancer research.

Original reporting
invezz.com
Published Oct 16, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 6:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$MRNA
Bearish
high confidence
Mentioned
$MRNA
Relevance
7/10
AlphAI data visualization · based on invezz.com
Decision brief

The 30-second read

$MRNABearishMed
01

Why it matters

The 10% drop highlights profit-taking and skepticism despite analyst target increase.

02

Market read

Moderna's sharp intraday move and mixed analyst signals suggest short-term volatility.

03

What to watch

Upcoming detailed trial data for the cancer vaccine could reverse sentiment if results are positive.

Relevance 7/10Novelty 6/10Timing: today

Background

Moderna's recent rally was driven by optimism around its personalized cancer vaccine partnership with Merck.

Company-level read

Ticker impact

$MRNABearishHigh confidence
Context

Moderna fell ~10% on Friday after a 25% rally; Goldman raised its price target to $137 but kept a Neutral rating.

Expected impact

likely pressure as the market prices in the target below current levels

Evidence & confidence

Goldman's target increase is modest relative to the share price, offering little support for the rally.

Market effects

Sector

Biotech sector may see modest pullback as peers react to Moderna's decline.

Regional

U.S. markets could see slight negative bias in healthcare stocks.

Global

Limited to investors tracking biotech valuations.

Counterpoint

What could challenge this read

The price dip may present a buying opportunity if the target raise signals confidence in long-term upside.

Key entities

  • Analyst
    Goldman Sachs

    Raised price target to $137, kept Neutral rating.

  • Partner
    Merck

    Collaborating on Moderna's personalized cancer vaccine.

Read at source← All news

Related articles

OCT 15
$MRNAMed

Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches

Moderna (MRNA) shares rose 4.5% as investors await detailed results from a Phase 3 cancer trial with Merck (MRK). The trial, involving 1,137 patients, showed the treatment reduced cancer recurrence. Results will be presented on October 24. Moderna reported a Q2 net loss of $782 million. Barclays estimates potential $3 billion annual melanoma sales by 2035, split equally with Merck.

tipranks.com6 min
OCT 15
$MRNAMed

Moderna (MRNA) Shares Surge on Cancer Vaccine Data Ahead of Late

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

gurufocus.com6 min
OCT 15
$MRNAHigh

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

247wallst.com2 min
OCT 15
$MRNAMed

MRNA Maintains Neutral Rating -- Price Target Raised to $137

Goldman Sachs maintained a Neutral rating on Moderna (MRNA) but raised its price target to $137 from $120. GuruFocus values MRNA at $23.84, suggesting it is 849.2% overvalued. The company has a GF Score of 54/100, with strengths in financial stability but weaknesses in profitability and valuation. Insider selling totaled $49.18M over the past three months.

gurufocus.com2 min